• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • About ALS
    • Understanding the Science
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Science on Target Blog

Target ALS Thought Leadership

Biomarkers: Pioneering Non-Invasive Tools for TDP-43 Detection

Biomarkers: Pioneering Non-Invasive Tools for TDP-43 Detection

Expanding ALS Research: Target ALS Global Natural History Study Launches in Israel

Expanding ALS Research: Target ALS Global Natural History Study Launches in Israel

Dr. Manish Raisinghani for the 2024 Target ALS Annual Meeting

Dr. Manish Raisinghani for the 2024 Target ALS Annual Meeting

Tackling TDP-43: A Systems-Level Approach to A Central Pathological driver of ALS

Tackling TDP-43: A Systems-Level Approach to A Central Pathological driver of ALS

Pioneering the Next Generation of ALS Therapeutics: Announcing the 2025 Novel Modalities Consortia Grantees

Pioneering the Next Generation of ALS Therapeutics: Announcing the 2025 Novel Modalities Consortia Grantees

Tofersen Shows Promising Results in SOD1 ALS Treatment—A New Hope for Genetic Therapies

Tofersen Shows Promising Results in SOD1 ALS Treatment—A New Hope for Genetic Therapies

The Innovation Ecosystem

Charting the Future of ALS Trials with Digital Twins: A Conversation with Dr. Robert McFarlane

Charting the Future of ALS Trials with Digital Twins: A Conversation with Dr. Robert McFarlane

A Personal Mission, A Global Lens: Dr. Senda Ajroud-Driss on the Promise of ALS Research

A Personal Mission, A Global Lens: Dr. Senda Ajroud-Driss on the Promise of ALS Research

Trailblazing a New Frontier in ALS Treatment: Dr. Claire Clelland’s Bold CRISPR Strategy to Rewrite the Future

Trailblazing a New Frontier in ALS Treatment: Dr. Claire Clelland’s Bold CRISPR Strategy to Rewrite the Future

Unlocking ALS Risk in South Asian Populations: Inside a Groundbreaking Genetic Study Led by India and the UK

Unlocking ALS Risk in South Asian Populations: Inside a Groundbreaking Genetic Study Led by India and the UK

Turning Sight into Insight: How Amydis Is Using the Retina to Rethink ALS Screening and Diagnostics 

Turning Sight into Insight: How Amydis Is Using the Retina to Rethink ALS Screening and Diagnostics 

Expanding the Frontiers of ALS Research: South Korea Joins the Target ALS Global Study

Expanding the Frontiers of ALS Research: South Korea Joins the Target ALS Global Study

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting